Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. METHODS: In this exploratory analysis, plasma biomarkers from baseline and week 4 from 621 of 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Powles, Thomas, Choueiri, Toni K., Motzer, Robert J., Jonasch, Eric, Pal, Sumanta, Tannir, Nizar M., Signoretti, Sabina, Kaldate, Rajesh, Scheffold, Christian, Wang, Evelyn, Aftab, Dana T., Escudier, Bernard, George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349489/
https://www.ncbi.nlm.nih.gov/pubmed/34364385
http://dx.doi.org/10.1186/s12885-021-08630-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349489/
https://www.ncbi.nlm.nih.gov/pubmed/34364385
http://dx.doi.org/10.1186/s12885-021-08630-w

Ejemplares similares